Tenaya Therapeutics Inc

NASDAQ TNYA

Data sourced from

and

Download Data

Tenaya Therapeutics Inc EBIT to Fixed Assets Ratio 2 year CAGR for the year ending December 31, 2023: 36.05%

Tenaya Therapeutics Inc EBIT to Fixed Assets Ratio 2 year CAGR is 36.05% for the year ending December 31, 2023, a 707.86% change year over year. The EBIT to Fixed Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of fixed assets (property, plant, and equipment). It indicates how efficiently a company utilizes its fixed assets to generate earnings. A higher ratio suggests better earnings generation from fixed assets, indicating improved operational efficiency and potentially higher profitability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Tenaya Therapeutics Inc EBIT to Fixed Assets Ratio for the year ending December 31, 2022 was -2.00, a -50.55% change year over year.
Tenaya Therapeutics Inc EBIT to Fixed Assets Ratio for the year ending December 31, 2021 was -1.33, a 41.22% change year over year.
Tenaya Therapeutics Inc EBIT to Fixed Assets Ratio for the year ending December 31, 2020 was -2.26, a 21.76% change year over year.
Tenaya Therapeutics Inc EBIT to Fixed Assets Ratio for the year ending December 31, 2019 was -2.89.

NASDAQ: TNYA

Tenaya Therapeutics Inc

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees	140
Sector	Healthcare
Industry	Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends